Insider Trading History of Foster-cheek Kaye I

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Foster-cheek Kaye I since 2018. This trader's CIK number is 1312622. At the time of last reporting, Foster-cheek Kaye I was the Director of Agios Pharmaceuticals, Inc.. (stock ticker symbol AGIO). Also see all insider trading activities at Agios Pharmaceuticals, Inc..


Yearly summary of insider trading at Agios Pharmaceuticals, Inc. (AGIO) by Foster-cheek Kaye I

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2025 AGIO 0 $0 0 $0 2,120 $0
2024 AGIO 0 $0 6,000 $191,529 3,388 $0
2023 AGIO 0 $0 25,000 $648,900 29,975 $452,250
2022 AGIO 0 $0 0 $0 1,585 $0
2020 AGIO 0 $0 0 $0 1,878 $0
2019 AGIO 0 $0 0 $0 1,400 $0
2018 AGIO 0 $0 15,800 $1,399,498 18,000 $882,540


Insider trading of Agios Pharmaceuticals, Inc. (AGIO) by Foster-cheek Kaye I

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2025-06-20 AGIO Option Ex 2,120 .00 0
2024-06-13 AGIO Option Ex 3,388 .00 0
2024-03-07 AGIO Sale 1,285 31.62 40,631
2024-03-05 AGIO Sale 300 32.21 9,663
2024-03-06 AGIO Sale 4,415 31.99 141,235
2023-08-09 AGIO Option Ex 25,000 18.09 452,250
2023-08-09 AGIO Sale 25,000 25.96 648,900
2023-06-21 AGIO Option Ex 4,975 .00 0
2022-05-20 AGIO Option Ex 1,585 .00 0
2020-05-29 AGIO Option Ex 1,878 .00 0
2019-05-31 AGIO Option Ex 1,400 .00 0
2018-06-14 AGIO Option Ex 9,000 50.73 456,570
2018-06-14 AGIO Sale 9,000 93.57 842,102
2018-03-19 AGIO Option Ex 6,800 47.33 321,844
2018-03-19 AGIO Sale 6,800 81.97 557,396
2018-02-26 AGIO Option Ex 2,200 47.33 104,126

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Foster-cheek Kaye I (Director of Agios Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.